MacuScopepptforWebsite.pptVIP

American Foundation for the Blind Headlines MacuScopeTM Accurately measures a patient’s Macular Protective Pigment Density (MPPD) Low MPPD is a major risk factor for Macular Degeneration and is modifiable Pigment deficiency can NOW be identified and monitored decades before clinical signs and/or symptoms appear The Science The FactsOverwhelming body of evidence that: Yellow MPP blocks high energy blue light has strong antioxidative properties resides anterior to the RPE layer and photoreceptors Consists solely of 3 carotenoids: Lutein (L), Meso-zeaxanthin (MZ) Zeaxanthin (Z) MZ is the dominant carotenoid at the fovea and is the most potent antioxidant in the macula Link to AMD AMD Patients have low MPPD - a major risk factor Reasons for low MPPD include: Genetics Smoking Dietary insufficiency Obesity Inability to absorb Lack of ability to convert L to MZ Age and Macular Pigment Cigarette Smoking and Macular Pigment Family History of AMD and Macular Pigment Nutraceutical Supplementation Repigmentation of the macula reduces the risk of developing AMD Objective: prevent future permanent and cumulative damage Appropriate nutraceutical supplementation can rebuild Macular Pigment a formulary containing all 3 carotenoids as found in LMZ3: 10mg Lutein: 10 mg Meso-zeaxanthin: 2 mg Zeaxanthin Measurable repigmentation can occur in as little as 6 months and usually plateaus in 2 years AREDS Report 22 Archives of Ophthalmology, Sept. ’07 Evaluated dietary intake of carotenoids, vitamins A, C and E and their relationship to the progression of AMD Conclusion: Only dietary intake of carotenoids correlated with a decreased rate of progression for any of the four stages of AMD Leading Expert John Nolan BSc, PhD Fulbright Scholar @ University of Georgia Deputy Director Post Doctoral Research Fellow, Waterford Institute of Technology PhD thesis Determinants of Macular Pigment in Healthy Subjects was the largest cross-sectional study of its type in the world Signific